Personalis shares fall 22.11% after-hours as company cuts 2025 revenue guidance and reports 44% Q3 revenue decline.

Personalis (NASDAQ:PSNL) fell 22.11% in after-hours trading following its third-quarter 2025 earnings report, which revealed mixed results despite beating revenue estimates. The company reported $14.5 million in revenue (above $13.31 million expected) but missed EPS forecasts (-$0.24 vs. -$0.28 expected) and cut full-year revenue guidance. Revenue declined 44% year-over-year in Q3, worsening from a 24% drop in Q2, driven by declines across biopharma, enterprise sales, and VA MVP segments. While Needham and other analysts raised price targets (e.g., $7–$10, $9–$11), citing growth in minimal residual disease testing, the market focused on the guidance reduction and persistent revenue weakness. The stock’s sharp after-hours drop reflects investor skepticism about the company’s near-term financial trajectory, despite long-term optimism around MRD testing expansion and pending reimbursement applications.